Continuing Medical Education (CME) for PHO Review Course On Demand, 2019 Edition
The American Society of Pediatric Hematology/Oncology (ASPHO) will offer CME credit for sessions viewed and evaluated. A certificate will be issued upon completion of the evaluation for the product.
The American Society of Pediatric Hematology/Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Society of Pediatric Hematology/Oncology designates this enduring material for a maximum of 27 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ASPHO offers its evaluation in an online format and it may be completed after viewing the sessions. Participants receive their certificates immediately when they submit their evaluation.
Disclosure
ASPHO requires that planners and presenters disclose the existence of any relevant financial or other relationship they and/or their spouse/partner have with the manufacturers of any commercial interest (defined as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients) whose products or services relate to the topics presented. ASPHO also requires disclosure of the intent to discuss unlabeled or investigational use(s) of a commercial product. The ASPHO Accreditation Subcommittee of the Education Committee reviews potential conflicts of interest as submitted by planners and presenters and resolves such conflicts to ensure the content of the activity is aligned with the interests of the public.
Disclaimer
The material presented in this activity represents the opinion of the speakers and not necessarily the views of ASPHO.
Review Course Committee
The committee is responsible for the course content, and faculty recruitment and development, with attention to the ABP subspecialty topic content, feedback from participants and changing requirements of maintenance of certification. The committee also directs the online review course program.
Guy Young, MD (Co-Chair)
Children’s Hospital Los Angeles
Los Angeles, CA
Paul Harker-Murray, MD PhD (Co-Chair)
Medical College of Wisconsin
Milwaukee, WI
Ibrahim Ahmed, MD MSC
Children’s Mercy Hospital
Kansas City, MO
Anthony Audino, MD
Nationwide Children’s Hospital
Columbus, OH
Hema Dave, MD, MPH
Children's National Medical Center
Washington, DC
Jonathan Fish, MD
Cohen Children’s Medical Center
New Hyde Park, NY
Melissa Frei-Jones, MD MSCI
UT Health Science Center
San Antonio, TX
Alex George, MD PhD
Texas Children’s Hospital
Houston, TX
Sajad Khazal, MB ChB
University of Texas MD Anderson Cancer Center
Houston, TX
Cindy E. Neunert, MD
Columbia University
New York, NY
Devang Pastakia, MD
Vanderbilt University
Nashville, TN
Michael Pulsipher, MD
Children’s Hospital Los Angeles
Los Angeles, CA
Hemalatha Geetharani Rangarajan, MD
Nationwide Children’s Hospital
Columbus, OH
Kayelyn Wagner, MD MME
Sanford Children’s Hospital
Sioux Falls, SD
Review Course Committee Disclosures:
No relevant financial relationships: Ibrahim Ahmed; Anthony Audino; Hema Dave; Melissa Frei-Jones; Alex George; Paul D. Harker-Murray; Sajad Khazal; Devang Pastakia; Hemalatha Rangarajan; Kayelyn Wagner; Guy Young
Relevant financial relationships: Cindy E. Neunert - Sanofi-Genzyme: Consultant, consultation fee; Jonathan Fish - Astrazeneca/Daiichi Sankyo: DSMB, stipend; Michael A. Pulsipher - Novartis: Advisory board, honorarium
Accreditation Subcommittee
No relevant financial relationships: Tanya Brown; Cathleen Cook; Mary-Jane Hogan; Jeffrey Hord; Seethal Jacob; Karen Lewing; Kate Mazur; Mukta Sharma
Staff
No relevant financial relationships: Jackie Holcomb; Cassie McGarigle
Speaker Disclosures
No relevant financial relationships and no discussion of off-label drug use:
Carl E. Allen; Michael P. Anderson; Patrick A. Brown; Karen E. Effinger; Mark D. Fleming; Melissa Frei-Jones; Paul D. Harker-Murray; Matthew M. Heeney; Jennifer C. Kesselheim; Jenny Moran; Matthew Oberley; Rowena C. Punzalan; Carlos Rodriguez-Galindo; Guy Young
No relevant financial relationships; off-label drug use discussed:
Denise M. Adams; Mignon L. Loh; Leo Mascarenhas; Kenneth L. McClain; Sung-Yun Pai; Julie R. Park; David O. Walterhouse
Relevant financial relationships and no discussion of off-label drug use:
Jason Fangusaro: Celgene - Pediatric oversight group, honorarium; Rachael F. Grace: Agios Pharmaceuticals- Clinical research, research funding; Michael A. Pulsipher - Novartis: Advisory board, honorarium; Zora R. Rogers: BCT Terumo - Medical monitor for clinical trial, honorarium
Relevant financial relationships; off-label drug use discussed:
Cindy E. Neunert: Sanofi-Genzyme - Consultant, consultant fee; Sarah H. O’Brien: Bristol Myers Squibb - Principal Investigator, research support
Learning Objectives
As a result of completing this activity, participants should be able to
- describe the basic pathophysiology of hematologic disease and cancer in infants, children, and adolescents, including molecular and cellular biology, the genetic and biochemical basis of disease, and the fundamentals of morphology and disease classification
- discuss the differential diagnosis, management, and outcomes of the hematologic disorders and malignancies encountered in practice by pediatric hematology/oncology specialists
- explain fundamental concepts of biostatistics, epidemiology and outcomes analysis, and engagement in scholarly activities as these areas apply to the field of pediatric hematology/oncology
- analyze the principles and practice of stem cell transplantation, transfusion medicine, and supportive care in children with hematologic disease and cancer, along with the basic principles of immunology and the most common immunologic disorders encountered by the hematologist
- prepare for the hematology/oncology subboard examination offered by the ABP and subsequent questions and examinations aimed at future Maintenance of Certification 3 requirements.